Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 103

1.

Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism.

Kim H, Yoo S, Zhou R, Xu A, Bernitz JM, Yuan Y, Gomes AM, Daniel MG, Su J, Demicco EG, Zhu J, Moore KA, Lee DF, Lemischka IR, Schaniel C.

Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):E11128-E11137. doi: 10.1073/pnas.1814044115. Epub 2018 Nov 1.

PMID:
30385632
2.

Pediatric Case of Li-Fraumeni Syndrome Complicated with Supratentorial Anaplastic Ependymoma.

Hosoya T, Kambe A, Nishimura Y, Sakamoto M, Maegaki Y, Kurosaki M.

World Neurosurg. 2018 Dec;120:125-128. doi: 10.1016/j.wneu.2018.08.203. Epub 2018 Sep 6.

PMID:
30196175
3.

Whole-body magnetic resonance imaging of Li-Fraumeni syndrome patients: observations from a two rounds screening of Brazilian patients.

Paixão D, Guimarães MD, de Andrade KC, Nóbrega AF, Chojniak R, Achatz MI.

Cancer Imaging. 2018 Aug 14;18(1):27. doi: 10.1186/s40644-018-0162-8.

4.

Surgical Treatment of Intramedullary Spinal Metastasis in Medulloblastoma: Case Report and Review of the Literature.

Goyal A, Cajigas I, Ibrahim GM, Brathwaite CD, Khatib Z, Niazi T, Bhatia S, Ragheb J.

World Neurosurg. 2018 Oct;118:42-46. doi: 10.1016/j.wneu.2018.06.250. Epub 2018 Jul 7. Review.

PMID:
29990605
5.

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells.

Zhou R, Xu A, Tu J, Liu M, Gingold JA, Zhao R, Lee DF.

J Vis Exp. 2018 Jun 13;(136). doi: 10.3791/57664.

PMID:
29985349
6.

What Should a Gynecologist Know about Li-Fraumeni Syndrome? Lessons from a Patient Undergoing Hysterectomy for Benign Indications.

Advolodkina P, Lachiewicz MP, Oprea-Ilies G, Majmudar B, Gordon AN.

Gynecol Obstet Invest. 2018;83(4):410-414. doi: 10.1159/000489261. Epub 2018 Jun 26.

PMID:
29945152
7.

Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience.

Murray KS, Spaliviero M, Tonorezos ES, Lacouture ME, Tap WD, Oeffinger KC, Vargas HA, Eastham JA.

Urology. 2018 Sep;119:55-61. doi: 10.1016/j.urology.2018.06.008. Epub 2018 Jun 21.

PMID:
29935265
8.

Breast implant-associated anaplastic large cell lymphoma in a Li-FRAUMENI patient: a case report.

Pastorello RG, D'Almeida Costa F, Osório CABT, Makdissi FBA, Bezerra SM, de Brot M, Campos AHJFM, Soares FA, Vassallo J.

Diagn Pathol. 2018 Jan 25;13(1):10. doi: 10.1186/s13000-018-0688-x.

9.

Atypical cutaneous melanocytic tumours arising in two patients with Li-Fraumeni syndrome.

Jacquemus J, Perron E, Pissaloux D, Alberti L, de la Fouchardière A.

Pathology. 2017 Dec;49(7):801-805. doi: 10.1016/j.pathol.2017.08.013. Epub 2017 Nov 3. No abstract available.

PMID:
29108654
10.

Is Li-Fraumeni syndrome really much more common?

Thomas DM.

Hum Mutat. 2017 Dec;38(12):1619. doi: 10.1002/humu.23342. No abstract available.

PMID:
29091331
11.

Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study.

O'Neill AF, Voss SD, Jagannathan JP, Kamihara J, Nibecker C, Itriago-Araujo E, Masciari S, Parker E, Barreto M, London WB, Garber JE, Diller L.

Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26822. Epub 2017 Oct 27.

PMID:
29077256
12.

Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome.

Amadou A, Waddington Achatz MI, Hainaut P.

Curr Opin Oncol. 2018 Jan;30(1):23-29. doi: 10.1097/CCO.0000000000000423. Review.

PMID:
29076966
13.

Identification and Management of TP53 Gene Carriers Detected Through Multigene Panel Testing.

Pal T, Brzosowicz J, Valladares A, Wiesner GL, Laronga C.

South Med J. 2017 Oct;110(10):643-648. doi: 10.14423/SMJ.0000000000000711.

PMID:
28973705
14.

Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile.

Franceschi S, Spugnesi L, Aretini P, Lessi F, Scarpitta R, Galli A, Congregati C, Caligo MA, Mazzanti CM.

Carcinogenesis. 2017 Sep 1;38(9):938-943. doi: 10.1093/carcin/bgx069.

PMID:
28911001
15.

Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history.

de Andrade KC, Mirabello L, Stewart DR, Karlins E, Koster R, Wang M, Gapstur SM, Gaudet MM, Freedman ND, Landi MT, Lemonnier N, Hainaut P, Savage SA, Achatz MI.

Hum Mutat. 2017 Dec;38(12):1723-1730. doi: 10.1002/humu.23320. Epub 2017 Sep 21.

PMID:
28861920
16.

Successful Treatment of Recurrent Li-Fraumeni Syndrome-related Choroid Plexus Carcinoma.

McEvoy M, Robison N, Manley P, Yock T, Konopka K, Brown RE, Wolff J, Green AL.

J Pediatr Hematol Oncol. 2017 Nov;39(8):e473-e475. doi: 10.1097/MPH.0000000000000965.

17.

Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.

Zhou R, Xu A, Gingold J, Strong LC, Zhao R, Lee DF.

Trends Pharmacol Sci. 2017 Oct;38(10):908-927. doi: 10.1016/j.tips.2017.07.004. Epub 2017 Aug 14. Review.

18.

Osteosarcoma: Molecular Pathogenesis and iPSC Modeling.

Lin YH, Jewell BE, Gingold J, Lu L, Zhao R, Wang LL, Lee DF.

Trends Mol Med. 2017 Aug;23(8):737-755. doi: 10.1016/j.molmed.2017.06.004. Epub 2017 Jul 20. Review.

19.

Li-Fraumeni versus Pseudo-Li-Fraumeni Syndrome: Key Insights for Interpreting Next-Generation Sequencing Reports in Patients with Suspected Cancer Predisposition Syndromes.

Sorscher S, Desnoyers R, Ouyang K, Ramkissoon S.

Oncologist. 2017 Sep;22(9):1084-1085. doi: 10.1634/theoncologist.2017-0016. Epub 2017 Jun 7. No abstract available.

20.

A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.

Llovet P, Illana FJ, Martín-Morales L, de la Hoya M, Garre P, Ibañez-Royo MD, Pérez-Segura P, Caldés T, García-Barberán V.

Fam Cancer. 2017 Oct;16(4):567-575. doi: 10.1007/s10689-017-9990-0.

PMID:
28573494

Supplemental Content

Loading ...
Support Center